Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Lal N, Mehra S, Lal V
Legal and regulatory risks Not approved as a drug, supplement, or food in the US, EU, Australia, and other major markets
16: e61951 doi: 10.7759/cureus.61951
Kobayati A, Haidar A, Tsoukas MA (2022) Glucagon-like peptide-1 receptor agonists as adjunctive treatment for type 1 diabetes: renewed opportunities through tailored approaches
Reported side effects are usually mild and short-lived
US$ 20.53
US$ 27.51
US$ 21.70
US$ 28.57
US$ 25.09
